Mipomersen

Antisense Oligonucleotide — CARDIOVASCULAR SYSTEM

Key facts

Mipomersen is a drug in the Antisense Oligonucleotide class catalogued in DrugCentral. It was first approved by the FDA in 2013. DrugCentral lists 1 molecular target, including APOB. Recorded indications include Familial hypercholesterolemia - homozygous.

• Drug class: Antisense Oligonucleotide; Apolipoprotein B-100 Synthesis Inhibitor.
• Molecular targets: APOB (1 listed in DrugCentral).
• Indications: Familial hypercholesterolemia - homozygous.
• ATC code: C10AX11 (Other lipid modifying agents).
• Molecular formula: C230H305N67Na19O122P19S19; molecular weight 7594.76 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Familial hypercholesterolemia - homozygous

Mechanism & targets

• Established pharmacologic class: Antisense Oligonucleotide; Apolipoprotein B-100 Synthesis Inhibitor

Molecular targets (1)

Target	Gene	Action	Activity
Apolipoprotein B-100 mRNA	APOB	other	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2013-01-29	FDA	—	GENZYME CORP	Yes

ATC classification

ATC code	Therapeutic hierarchy
C10AX11	CARDIOVASCULAR SYSTEM › LIPID MODIFYING AGENTS › LIPID MODIFYING AGENTS, PLAIN › Other lipid modifying agents

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• FDA label: LDLR

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Injection site pain	89.3

Chemical structure

• Molecular formula: C₂₃₀H₃₀₅N₆₇Na₁₉O₁₂₂P₁₉S₁₉
• Molecular weight: 7594.76 g/mol
• CAS number: 629167-92-6
• InChIKey: —
• PubChem CID: 71301230

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Mipomersen used for?

DrugCentral lists the following indications for Mipomersen: Familial hypercholesterolemia - homozygous.

How does Mipomersen work?

Its molecular targets in DrugCentral include APOB.

When was Mipomersen first approved?

Mipomersen was first approved by the FDA in 2013.

What drug class does Mipomersen belong to?

Mipomersen is in the Antisense Oligonucleotide class.

What is the chemical formula of Mipomersen?

Mipomersen has the molecular formula C230H305N67Na19O122P19S19 and a molecular weight of 7594.76 g/mol.

Sources

• DrugCentral drug card 4747 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2219536 — compound record and bioactivity
• PubChem CID 71301230 — chemical identifiers
• DrugBank DB05528 — drug record
• FDA UNII 9GJ8S4GU0M — substance identity
• DailyMed: FDA labels for Mipomersen — current prescribing information (label search)
• UniProt P04114 (APOB) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.